Short Term Effects of Synchronized vs. Non-synchronized NIPPV in Preterm Infants.
NCT ID: NCT03289936
Last Updated: 2023-11-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-11-16
Study Completion Date
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Comparing the cardio-respiratory adaptation and differences to non invasive ventilation techniques, nasal intermittent positive pressure ventilation (NIPPV) non synchronized vs synchronized (SNIPPV) in preterm newborns (gestational age at birth \< 32 weeks) at their first approach to non invasive ventilation as first intention (soon after birth) or after extubation.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Respiratory problems are one of the major issues to deal with in preterm newborns.
Because of the immaturity of respiratory mechanisms and structures, the use of supporting devices is often necessary. These include both conventional mechanical ventilation (MV) techniques, which require the use of an endotracheal tube, as well as non-invasive ventilation (NIV) techniques that use softer ventilator-patient interfaces. Increasing attention is payed to the latter ones as less aggressive and associated with better outcomes both in terms of mortality and short and long-term complications, such as bronchopulmonary dysplasia (BPD).
Nasal intermittent positive pressure ventilation (NIPPV) is a NIV technique in which newborn airways are kept open between two pressure levels: peak inspiratory pressure (PIP) and positive end expiratory pressure (PEEP). The frequency and duration of each phase are defined by setting the inspiratory and expiratory times or the ventilation rate.
This technique has already shown its superiority in terms of reduced duration of MV, reduced necessity of intubation, decreased failure of extubating and reduced prevalence of BPD if compared with non-invasive techniques based on continuous pressure support, such as continuous positive airway pressure (CPAP). Recent meta-analyses of studies where NIPPV has been used as an alternative to CPAP following extubation show that it reduces need for re-ventilation and air leaks but without any reduction in BPD: there is insufficient evidence to recommend NIPPV as primary mode of respiratory support in the delivery room.
It should be specified that the ventilation rate on NIPPV does not reflect the real respiratory rate (RR) of the newborn, as the ventilator supplies the PIP regardless of newborn respiratory efforts. To reproduce a more physiological and gentle ventilation new devices able to detect newborn respiratory efforts and consequently supply a PIP have been developed to synchronize the ventilation rate with RR of the newborn.
The devices used for synchronization can identify newborn respiratory effort by detecting variation in flow or pressure. While in MV the exact beginning of inspiration can be detected through a continuous monitoring of pressure or through the precise interception of inspiratory and expiratory flow some difficulties occur in NIV where, as a consequence of the impossibility to detect expiratory flow, the moment of the exact beginning of spontaneous inspiration is hard to identify.
Recently, a new type of NIV ventilator equipped with a pressure sensor has been put on the market. The software of this ventilator is able to calculate the flow according to the pressure variations of the circuit and to capture the flow variations induced by spontaneous breathing allowing a synchronization of the flow with the patient's respiratory acts.
The use of a synchronized NIV technique would allow a more physiological respiratory support, reducing respiratory fatigue and improving newborn compliance. Despite these premises, the diffusion of synchronized NIPPV in neonatal intensive care units (NICUs) and works on its efficacy are limited.
Some authors have already demonstrated the benefits of using a synchronized NIV technique in terms of extubating success rate, BPD prevalence and mortality and neurocognitive development. Synchronized NIPPV (SNIPPV) seems more effective than NIPPV and NCPAP in reducing need for intubation in respiratory distress syndrome (RDS), in improving the success of extubation and in treating apnea of prematurity, with a reassuring absence of relevant side effects. Synchronised NIPPV delivered through a ventilator can reduce extubation failure but may not confer long-term advantages such as reduction in BPD. Other reported advantageous aspects of SNIPPV include improved thoraco-abdominal synchrony, reduced work of breathing (WOB) and reduced need of intubation.
It has already been shown that SNIPPV is more effective than NIPPV and CPAP in reducing the number of desaturations and apnoea in preterm infants undergoing CPAP treatment for prematurity apnoea. However, the effectiveness of SNIPPV compared to NIPPV in preterm infants with respiratory distress is still not completely clear.
Our study protocol was designed to evaluate the short-term effects of SNIPPV vs NIPPV on the major cardio-respiratory variables, trying to identify the best ventilation modality for preterm newborns at their first approach to NIV ventilation support, on the bases of cardio-respiratory events reduction and fraction of inspired oxygen (FiO2) request.
NUMBER OF PATIENTS The number of patients to be enrolled is calculated based on a predicted difference of 30% in cardio-respiratory events between the two ventilation modalities. Assuming a mean of 5 and a SD of 1.5 events/hour (based on available literature data), the number of patients to be enrolled is 30, to obtain an 80% power and a significance threshold of 0.05.
STUDY DESIGN The decision to use a NIV support is based on clinical evaluation. At starting of NIV, eligible patients will be allocated to one of the two arms (NIPPV or SNIPPV) by block randomization. A custom software will be used to obtain a casual sequence to randomize patients in both arms, creating a balance between patients needing NIV as first intention or after extubating.
After 2 hours of stabilization (stabilization phase) in NIV, enrolled patients will be alternatively ventilated with 2 different techniques for 2 time frame of 4 hours each.
In case of needing surfactant, the stabilization phase will be 4 hours after its administration.
Infants will be kept supine throughout the study. During the whole study duration (including stabilization phase) all patients will be continuously monitored with a multiparametric monitor, recording also data from the ventilator. The first hour of each NIPPV/SNIPPV phase will be considered as wash-out phase and named "adaptation phase": data recorded during this phase are excluded from the analysis. Milk meals will be administered during the adaptation phase.
Pain and compliance scales will be filled in by nurses every 60 minutes. EGA values will be recorded at the end of the stabilization phase, at the end of Phase A (first NIV modality) and Phase B (second NIV modality).
Patients will considered drop out of the study in case of:
1. NIV failure criteria: FiO2 \> 40%, pH \< 7.2, pCO2 \> 65mmHg, ≥ 3 episodes of desaturations (transcutaneous O2 saturation (SatO2 TC) \< 80%) per hour, ≥ 3 episodes of apnea (\> 20 s) and/or bradycardia (heart rate (HR) \< 80 beats per minute (bpm)) per hour, Silverman score \>6. Necrotizing enterocolitis, bowel perforation, and hemodynamic instability as indications of NIV failure
2. Air leak syndrome (i.e. pneumothorax)
3. Needing of invasive procedures during the study
4. Needing of surfactant during the study
5. Development of hemodynamic instability or surgical problems during the study
6. Death Data obtained from dropouts (patients who drop out of the study) will be analyzed separately.
After 8 hours of study, each patient will be ventilated with the best NIV modality according to clinical data and cardio-respiratory parameters observed during the study.
MONITORING Nurse staff will continuously monitor patients to avoid biases due to device wrong positioning
DATA
For each patient enrolled the following variables will be collected:
* ANAMNESTIC VARIABLES:
* Gestational age at birth
* Birth weight
* Delivery type
* APGAR at 1/5 minutes (and 10 minutes if available)
* Presence of intrauterine growth restriction
* Maternal administration of magnesium sulphate
* Steroid prenatal prophylaxis (number of doses)
* Intrapartum antibiotic prophylaxis (if indicated)
* Presence of intraamniotic infection and administration of intrapartum antibiotic therapy
* CLINICAL VARIABLES
* Surfactant administration (time and number of doses)
* Type and duration of MV previously administered (if any)
* Type and duration of NIV previously administered (if any)
* Corrected GA at enrolling
* Caffeine doses administered (if any)
* Neonatal Pain Scale score
* CARDIO-RESPIRATORY VARIABLES
* FiO2 to maintain SatO2 TC 90-94% (as weighted mean)
* NIV failure and endotracheal intubation
* Number of cardiorespiratory events, defined as episodes of apnea lasting more than 20 seconds or over 5 seconds if followed by desaturation or bradycardia and/or episodes of desaturation with blood oxygen saturation below 80% for 4 sec. or more and/or episodes of bradycardia with heart rate below 80 bpm
* OTHER POLYGRAPH VARIABLES (continuous monitoring)
* Heart rate
* Respiratory rate
* SatO2 TC
* Thoracic impedance
* From ventilator: trigger, pressure, flow
* Pressure in ventilator circuit
* LABORATORISTIC VARIABLES
* EGA values at the end of stabilization phase, Phase A and Phase B
RESULTS INTERPRETATION The main result will be the difference in cardio-respiratory events during SNIPPV versus NIPPV.
Tolerance to each of the two NIV modalities will be evaluated by evaluating the number of failure episodes and of cardio-respiratory events and analysing the scores for individual compliance and pain. The individual need for oxygen under the two modalities of NIV will be evaluated as a known risk factor for premature retinopathy and various other complications.
STATISTICAL ANLYSES Descriptive variables will be analyzed in function of their distribution. T student test or Mann Whitney U test in case of continuous variables (if normally or not normally distributed respectively) and chi-squared or fisher test for qualitative ones. All test will be two-sided with a significance threshold of 0.05.
EXPECTED RESULTS Identifying the best NIV modality for preterm newborns at their first approach to NIV ventilation support, on the bases of cardio-respiratory events reduction and fraction of inspired oxygen (FiO2) request.
Because of the immaturity of respiratory mechanisms and structures, the use of supporting devices is often necessary. These include both conventional mechanical ventilation (MV) techniques, which require the use of an endotracheal tube, as well as non-invasive ventilation (NIV) techniques that use softer ventilator-patient interfaces. Increasing attention is payed to the latter ones as less aggressive and associated with better outcomes both in terms of mortality and short and long-term complications, such as bronchopulmonary dysplasia (BPD).
Nasal intermittent positive pressure ventilation (NIPPV) is a NIV technique in which newborn airways are kept open between two pressure levels: peak inspiratory pressure (PIP) and positive end expiratory pressure (PEEP). The frequency and duration of each phase are defined by setting the inspiratory and expiratory times or the ventilation rate.
This technique has already shown its superiority in terms of reduced duration of MV, reduced necessity of intubation, decreased failure of extubating and reduced prevalence of BPD if compared with non-invasive techniques based on continuous pressure support, such as continuous positive airway pressure (CPAP). Recent meta-analyses of studies where NIPPV has been used as an alternative to CPAP following extubation show that it reduces need for re-ventilation and air leaks but without any reduction in BPD: there is insufficient evidence to recommend NIPPV as primary mode of respiratory support in the delivery room.
It should be specified that the ventilation rate on NIPPV does not reflect the real respiratory rate (RR) of the newborn, as the ventilator supplies the PIP regardless of newborn respiratory efforts. To reproduce a more physiological and gentle ventilation new devices able to detect newborn respiratory efforts and consequently supply a PIP have been developed to synchronize the ventilation rate with RR of the newborn.
The devices used for synchronization can identify newborn respiratory effort by detecting variation in flow or pressure. While in MV the exact beginning of inspiration can be detected through a continuous monitoring of pressure or through the precise interception of inspiratory and expiratory flow some difficulties occur in NIV where, as a consequence of the impossibility to detect expiratory flow, the moment of the exact beginning of spontaneous inspiration is hard to identify.
Recently, a new type of NIV ventilator equipped with a pressure sensor has been put on the market. The software of this ventilator is able to calculate the flow according to the pressure variations of the circuit and to capture the flow variations induced by spontaneous breathing allowing a synchronization of the flow with the patient's respiratory acts.
The use of a synchronized NIV technique would allow a more physiological respiratory support, reducing respiratory fatigue and improving newborn compliance. Despite these premises, the diffusion of synchronized NIPPV in neonatal intensive care units (NICUs) and works on its efficacy are limited.
Some authors have already demonstrated the benefits of using a synchronized NIV technique in terms of extubating success rate, BPD prevalence and mortality and neurocognitive development. Synchronized NIPPV (SNIPPV) seems more effective than NIPPV and NCPAP in reducing need for intubation in respiratory distress syndrome (RDS), in improving the success of extubation and in treating apnea of prematurity, with a reassuring absence of relevant side effects. Synchronised NIPPV delivered through a ventilator can reduce extubation failure but may not confer long-term advantages such as reduction in BPD. Other reported advantageous aspects of SNIPPV include improved thoraco-abdominal synchrony, reduced work of breathing (WOB) and reduced need of intubation.
It has already been shown that SNIPPV is more effective than NIPPV and CPAP in reducing the number of desaturations and apnoea in preterm infants undergoing CPAP treatment for prematurity apnoea. However, the effectiveness of SNIPPV compared to NIPPV in preterm infants with respiratory distress is still not completely clear.
Our study protocol was designed to evaluate the short-term effects of SNIPPV vs NIPPV on the major cardio-respiratory variables, trying to identify the best ventilation modality for preterm newborns at their first approach to NIV ventilation support, on the bases of cardio-respiratory events reduction and fraction of inspired oxygen (FiO2) request.
NUMBER OF PATIENTS The number of patients to be enrolled is calculated based on a predicted difference of 30% in cardio-respiratory events between the two ventilation modalities. Assuming a mean of 5 and a SD of 1.5 events/hour (based on available literature data), the number of patients to be enrolled is 30, to obtain an 80% power and a significance threshold of 0.05.
STUDY DESIGN The decision to use a NIV support is based on clinical evaluation. At starting of NIV, eligible patients will be allocated to one of the two arms (NIPPV or SNIPPV) by block randomization. A custom software will be used to obtain a casual sequence to randomize patients in both arms, creating a balance between patients needing NIV as first intention or after extubating.
After 2 hours of stabilization (stabilization phase) in NIV, enrolled patients will be alternatively ventilated with 2 different techniques for 2 time frame of 4 hours each.
In case of needing surfactant, the stabilization phase will be 4 hours after its administration.
Infants will be kept supine throughout the study. During the whole study duration (including stabilization phase) all patients will be continuously monitored with a multiparametric monitor, recording also data from the ventilator. The first hour of each NIPPV/SNIPPV phase will be considered as wash-out phase and named "adaptation phase": data recorded during this phase are excluded from the analysis. Milk meals will be administered during the adaptation phase.
Pain and compliance scales will be filled in by nurses every 60 minutes. EGA values will be recorded at the end of the stabilization phase, at the end of Phase A (first NIV modality) and Phase B (second NIV modality).
Patients will considered drop out of the study in case of:
1. NIV failure criteria: FiO2 \> 40%, pH \< 7.2, pCO2 \> 65mmHg, ≥ 3 episodes of desaturations (transcutaneous O2 saturation (SatO2 TC) \< 80%) per hour, ≥ 3 episodes of apnea (\> 20 s) and/or bradycardia (heart rate (HR) \< 80 beats per minute (bpm)) per hour, Silverman score \>6. Necrotizing enterocolitis, bowel perforation, and hemodynamic instability as indications of NIV failure
2. Air leak syndrome (i.e. pneumothorax)
3. Needing of invasive procedures during the study
4. Needing of surfactant during the study
5. Development of hemodynamic instability or surgical problems during the study
6. Death Data obtained from dropouts (patients who drop out of the study) will be analyzed separately.
After 8 hours of study, each patient will be ventilated with the best NIV modality according to clinical data and cardio-respiratory parameters observed during the study.
MONITORING Nurse staff will continuously monitor patients to avoid biases due to device wrong positioning
DATA
For each patient enrolled the following variables will be collected:
* ANAMNESTIC VARIABLES:
* Gestational age at birth
* Birth weight
* Delivery type
* APGAR at 1/5 minutes (and 10 minutes if available)
* Presence of intrauterine growth restriction
* Maternal administration of magnesium sulphate
* Steroid prenatal prophylaxis (number of doses)
* Intrapartum antibiotic prophylaxis (if indicated)
* Presence of intraamniotic infection and administration of intrapartum antibiotic therapy
* CLINICAL VARIABLES
* Surfactant administration (time and number of doses)
* Type and duration of MV previously administered (if any)
* Type and duration of NIV previously administered (if any)
* Corrected GA at enrolling
* Caffeine doses administered (if any)
* Neonatal Pain Scale score
* CARDIO-RESPIRATORY VARIABLES
* FiO2 to maintain SatO2 TC 90-94% (as weighted mean)
* NIV failure and endotracheal intubation
* Number of cardiorespiratory events, defined as episodes of apnea lasting more than 20 seconds or over 5 seconds if followed by desaturation or bradycardia and/or episodes of desaturation with blood oxygen saturation below 80% for 4 sec. or more and/or episodes of bradycardia with heart rate below 80 bpm
* OTHER POLYGRAPH VARIABLES (continuous monitoring)
* Heart rate
* Respiratory rate
* SatO2 TC
* Thoracic impedance
* From ventilator: trigger, pressure, flow
* Pressure in ventilator circuit
* LABORATORISTIC VARIABLES
* EGA values at the end of stabilization phase, Phase A and Phase B
RESULTS INTERPRETATION The main result will be the difference in cardio-respiratory events during SNIPPV versus NIPPV.
Tolerance to each of the two NIV modalities will be evaluated by evaluating the number of failure episodes and of cardio-respiratory events and analysing the scores for individual compliance and pain. The individual need for oxygen under the two modalities of NIV will be evaluated as a known risk factor for premature retinopathy and various other complications.
STATISTICAL ANLYSES Descriptive variables will be analyzed in function of their distribution. T student test or Mann Whitney U test in case of continuous variables (if normally or not normally distributed respectively) and chi-squared or fisher test for qualitative ones. All test will be two-sided with a significance threshold of 0.05.
EXPECTED RESULTS Identifying the best NIV modality for preterm newborns at their first approach to NIV ventilation support, on the bases of cardio-respiratory events reduction and fraction of inspired oxygen (FiO2) request.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Newborn Respiratory Distress
Preterm Infant
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Start ventilation with NIPPV
Alternatively vented with NIPPV and SNIPPV
Group Type
EXPERIMENTAL
NIPPV
Intervention Type
DEVICE
Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
SNIPPV
Intervention Type
DEVICE
Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
Start ventilation with SNIPPV
Alternatively vented with SNIPPV and NIPPV
Group Type
EXPERIMENTAL
NIPPV
Intervention Type
DEVICE
Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
SNIPPV
Intervention Type
DEVICE
Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NIPPV
Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
Intervention Type
DEVICE
SNIPPV
Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age at birth \<32 weeks
* First approach to NIV ventilation (primary or after extubation)
* Parent's informed consent
* First approach to NIV ventilation (primary or after extubation)
* Parent's informed consent
Exclusion Criteria
* Neurological (including IVH \> 2° grade) or surgical diseases
* Sepsis (clinical or laboratory confirmed)
* Chromosomal or genetic abnormalities
* Major malformations and congenital anomalies
* Cardiac problems (including hemodynamically significant PDA)
* Contraindication to NIV (i.e. nasal trauma and gastrointestinal surgery within the previous 7 days).
* Sepsis (clinical or laboratory confirmed)
* Chromosomal or genetic abnormalities
* Major malformations and congenital anomalies
* Cardiac problems (including hemodynamically significant PDA)
* Contraindication to NIV (i.e. nasal trauma and gastrointestinal surgery within the previous 7 days).
Maximum Eligible Age
32 Weeks
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Turin, Italy
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francesco Cresi, MD, PhD
MD, PhD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesco Cresi, PhD
Role: STUDY_CHAIR
Città della Salute e della Scienza - Ospedale S.Anna - University of Turin
Alessandra Coscia, Prof.
Role: STUDY_DIRECTOR
Città della Salute e della Scienza - Ospedale S.Anna - University of Turin
Elena Maggiora, MD
Role: PRINCIPAL_INVESTIGATOR
Città della Salute e della Scienza - Ospedale S.Anna - University of Turin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedale S.Anna di Torino
Torino, (TO), Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Moretti C, Giannini L, Fassi C, Gizzi C, Papoff P, Colarizi P. Nasal flow-synchronized intermittent positive pressure ventilation to facilitate weaning in very low-birthweight infants: unmasked randomized controlled trial. Pediatr Int. 2008 Feb;50(1):85-91. doi: 10.1111/j.1442-200X.2007.02525.x.
Reference Type
BACKGROUND
Gizzi C, Montecchia F, Panetta V, Castellano C, Mariani C, Campelli M, Papoff P, Moretti C, Agostino R. Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial. Arch Dis Child Fetal Neonatal Ed. 2015 Jan;100(1):F17-23. doi: 10.1136/archdischild-2013-305892. Epub 2014 Oct 15.
Reference Type
BACKGROUND
Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432-450. doi: 10.1159/000499361. Epub 2019 Apr 11.
Reference Type
BACKGROUND
Cummings JJ, Polin RA; Committee on Fetus and Newborn, American Academy of Pediatrics. Noninvasive Respiratory Support. Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-3758. Epub 2015 Dec 29.
Reference Type
BACKGROUND
Isayama T, Iwami H, McDonald S, Beyene J. Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis. JAMA. 2016 Aug 9;316(6):611-24. doi: 10.1001/jama.2016.10708.
Reference Type
BACKGROUND
Owen LS, Manley BJ. Nasal intermittent positive pressure ventilation in preterm infants: Equipment, evidence, and synchronization. Semin Fetal Neonatal Med. 2016 Jun;21(3):146-53. doi: 10.1016/j.siny.2016.01.003. Epub 2016 Feb 26.
Reference Type
BACKGROUND
Permall DL, Pasha AB, Chen XQ. Current insights in non-invasive ventilation for the treatment of neonatal respiratory disease. Ital J Pediatr. 2019 Aug 19;45(1):105. doi: 10.1186/s13052-019-0707-x.
Reference Type
BACKGROUND
Ferguson KN, Roberts CT, Manley BJ, Davis PG. Interventions to Improve Rates of Successful Extubation in Preterm Infants: A Systematic Review and Meta-analysis. JAMA Pediatr. 2017 Feb 1;171(2):165-174. doi: 10.1001/jamapediatrics.2016.3015.
Reference Type
BACKGROUND
Lemyre B, Davis PG, De Paoli AG, Kirpalani H. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev. 2017 Feb 1;2(2):CD003212. doi: 10.1002/14651858.CD003212.pub3.
Reference Type
BACKGROUND
Moretti C, Gizzi C, Montecchia F, Barbara CS, Midulla F, Sanchez-Luna M, Papoff P. Synchronized Nasal Intermittent Positive Pressure Ventilation of the Newborn: Technical Issues and Clinical Results. Neonatology. 2016;109(4):359-65. doi: 10.1159/000444898. Epub 2016 Jun 3.
Reference Type
BACKGROUND
Charles E, Hunt KA, Rafferty GF, Peacock JL, Greenough A. Work of breathing during HHHFNC and synchronised NIPPV following extubation. Eur J Pediatr. 2019 Jan;178(1):105-110. doi: 10.1007/s00431-018-3254-3. Epub 2018 Oct 30.
Reference Type
BACKGROUND
Salvo V, Lista G, Lupo E, Ricotti A, Zimmermann LJ, Gavilanes AW, Barberi I, Colivicchi M, Temporini F, Gazzolo D. Noninvasive ventilation strategies for early treatment of RDS in preterm infants: an RCT. Pediatrics. 2015 Mar;135(3):444-51. doi: 10.1542/peds.2014-0895. Epub 2015 Feb 9.
Reference Type
BACKGROUND
Manley BJ, Doyle LW, Owen LS, Davis PG. Extubating Extremely Preterm Infants: Predictors of Success and Outcomes following Failure. J Pediatr. 2016 Jun;173:45-9. doi: 10.1016/j.jpeds.2016.02.016. Epub 2016 Mar 5.
Reference Type
BACKGROUND
Alexiou S, Panitch HB. Physiology of non-invasive respiratory support. Semin Fetal Neonatal Med. 2016 Jun;21(3):174-80. doi: 10.1016/j.siny.2016.02.007. Epub 2016 Feb 28.
Reference Type
BACKGROUND
Li W, Long C, Zhangxue H, Jinning Z, Shifang T, Juan M, Renjun L, Yuan S. Nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure for preterm infants with respiratory distress syndrome: a meta-analysis and up-date. Pediatr Pulmonol. 2015 Apr;50(4):402-9. doi: 10.1002/ppul.23130. Epub 2014 Nov 21.
Reference Type
BACKGROUND
Handoka NM, Azzam M, Gobarah A. Predictors of early synchronized non-invasive ventilation failure for infants < 32 weeks of gestational age with respiratory distress syndrome. Arch Med Sci. 2019 May;15(3):680-687. doi: 10.5114/aoms.2019.83040. Epub 2019 Feb 18.
Reference Type
BACKGROUND
Aghai ZH, Saslow JG, Nakhla T, Milcarek B, Hart J, Lawrysh-Plunkett R, Stahl G, Habib RH, Pyon KH. Synchronized nasal intermittent positive pressure ventilation (SNIPPV) decreases work of breathing (WOB) in premature infants with respiratory distress syndrome (RDS) compared to nasal continuous positive airway pressure (NCPAP). Pediatr Pulmonol. 2006 Sep;41(9):875-81. doi: 10.1002/ppul.20461.
Reference Type
BACKGROUND
Huang L, Mendler MR, Waitz M, Schmid M, Hassan MA, Hummler HD. Effects of Synchronization during Noninvasive Intermittent Mandatory Ventilation in Preterm Infants with Respiratory Distress Syndrome Immediately after Extubation. Neonatology. 2015;108(2):108-14. doi: 10.1159/000431074. Epub 2015 Jun 17.
Reference Type
BACKGROUND
Bhandari V. Noninvasive respiratory support in the preterm infant. Clin Perinatol. 2012 Sep;39(3):497-511. doi: 10.1016/j.clp.2012.06.008.
Reference Type
BACKGROUND
Gizzi C, Papoff P, Giordano I, Massenzi L, Barbara CS, Campelli M, Panetta V, Agostino R, Moretti C. Flow-synchronized nasal intermittent positive pressure ventilation for infants <32 weeks' gestation with respiratory distress syndrome. Crit Care Res Pract. 2012;2012:301818. doi: 10.1155/2012/301818. Epub 2012 Nov 27.
Reference Type
BACKGROUND
Cresi F, Chiale F, Maggiora E, Borgione SM, Ferroglio M, Runfola F, Maiocco G, Peila C, Bertino E, Coscia A. Short-term effects of synchronized vs. non-synchronized NIPPV in preterm infants: study protocol for an unmasked randomized crossover trial. Trials. 2021 Jun 14;22(1):392. doi: 10.1186/s13063-021-05351-0.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SyncNIV
Identifier Type: -
Identifier Source: org_study_id